<!--
title: The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer
description: doi: 10.15252/emmm.201404084
published: true
date: 2022-02-11T13:30:39.818Z
tags: ivermectin, treatment, cancer, cure, macrocyclic, lactines, inhibit
editor: ckeditor
dateCreated: 2022-02-11T13:30:39.818Z
-->

<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287931/#">EMBO Mol Med.</a> 2014 Oct; 6(10): 1263–1278.</p>
<p>Published online 2014 Aug 20. doi:&nbsp;<a href="https://dx.doi.org/10.15252%2Femmm.201404084">10.15252/emmm.201404084</a></p>
<p style="text-align:right;">PMCID: PMC4287931</p>
<p style="text-align:right;">PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/25143352">25143352</a></p>
<p>&nbsp;</p>
<h1>The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer</h1>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Melotti%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Alice Melotti</a>,<sup>*</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Mas%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Christophe Mas</a>,<sup>*</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Kuciak%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Monika Kuciak</a>,<sup>*</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Lorente-Trigos%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Aiala Lorente-Trigos</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Borges%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Isabel Borges</a>, and <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ruiz%20i%20Altaba%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25143352">Ariel Ruiz i Altaba</a><sup>†</sup></p>
<h2>&nbsp;</h2>
<p style="text-align:right;">&nbsp;</p>
<h2>Abstract</h2>
<p>Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed a repositioning screen for WNT-TCF response blockers aiming to recapitulate the genetic blockade afforded by dominant-negative TCF. We report that Ivermectin inhibits the expression of WNT-TCF targets, mimicking dnTCF, and that its low concentration effects are rescued by direct activation by TCF<sup>VP16</sup>. Ivermectin inhibits the proliferation and increases apoptosis of various human cancer types. It represses the levels of C-terminal β-CATENIN phosphoforms and of CYCLIN D1 in an okadaic acid-sensitive manner, indicating its action involves protein phosphatases.<i>In vivo</i>, Ivermectin selectively inhibits TCF-dependent, but not TCF-independent, xenograft growth without obvious side effects. Analysis of single semi-synthetic derivatives highlights Selamectin, urging its clinical testing and the exploration of the macrocyclic lactone chemical space. Given that Ivermectin is a safe anti-parasitic agent used by &gt;&nbsp;200 million people against river blindness, our results suggest its additional use as a therapeutic WNT-TCF pathway response blocker to treat WNT-TCF-dependent diseases including multiple cancers.</p>
<p>&nbsp;</p>
<p>Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287931/</p>
